Loading...
Loading...
PLRX| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 1.1M |
| Gross Profit | -0.9M |
| Operating Expense | 47.6M |
| Operating I/L | -47.3M |
| Other Income/Expense | 6.1M |
| Interest Income | 6.5M |
| Pretax | -41.2M |
| Income Tax Expense | 6.5M |
| Net Income/Loss | -41.2M |
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for fibrosis and related diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, and is working on two preclinical integrin-based programs, including an oncology program and a program for an allosteric agonistic monoclonal antibody for muscular dystrophies. Pliant Therapeutics generates revenue through the development and potential commercialization of these innovative therapies.
